A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Gretchen Glaser et al.|Clinical Cancer Research|2024Cited by 15
Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021Stuart A. Ostby, Matthew S. Block, Eleftheria Kalogera et al.|Gynecologic Oncology Reports|2024Cited by 2
A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308)Matthew S. Block, Svetomir N. Markovic, Eleftheria Kalogera et al.|Gynecologic Oncology|2023Cited by 1
Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0
Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0